other material
confidence high
sentiment positive
materiality 0.45
Beyond Air subsidiary NeuroNOS secures $2M initial funding for autism therapy development
Beyond Air, Inc.
- NeuroNOS raised $2M initial equity from private investors as part of a larger round up to $5M total.
- Proceeds will accelerate preclinical development of a small-molecule drug targeting nitric oxide dysregulation in autism.
- First-in-human clinical trial anticipated to begin in 2026; formulation optimization for subcutaneous injection underway.
- After initial close, Beyond Air Ireland holds ~88% of NeuroNOS; would fall to ~75% if all $5M shares sold.
- Drug stems from Hebrew University research showing NO inhibition improves autism phenotypes in animal models.